tbuckley/cabot-search huggingface dataset:
Abstract 934: Chromokinesin KIF4 facilitates chromatin organization critical for immunoglobulin class switch recombination and prevents lymphoma formation
Authors: Manjari Mazumdar, Siddharth Dasari, Jennifer Keen
Journal: Cancer Research (2011)

Abstract Un-repaired DNA damage and chromosomal translocations are the major causes of genomic instability found in various human cancers. We have observed spontaneous B-cell Follicular lymphomas (FL) in a knock-out (KO) mouse model generated by gene trapping of KIF4, a unique DNA-binding, nuclear and chromatin-associated molecular motor. We have previously shown that KIF4 is an important modulator of higher-order chromatin structure and is required for maintaining genomic stability. Since FL often results from altered levels of DNA recombination of the immune system caused by chromosome structural changes, we investigated the contributions of KIF4 in regulating chromatin structure for B cell function. We show that there is an abnormal proliferation of B cells in mice in both bone marrow and spleen of young adult mice lacking KIF4 function. Chromosome spread from young adult knockout and neoplastic splenocytes show abnormal chromosome numbers (aneuploidy) and structure in the absence of KIF4 indicating that KIF4 is critical in maintaining genome integrity in vivo. Maintaining and establishing a stable but dynamic chromatin organization is critical for successful class switch recombination during B cell development. We observed that immunoglobulin (Ig) class switch recombination (CSR) in activated B cells is severely impaired in the absence of KIF4. Moreover, our biochemical and proteomic analysis reveals that repressive chromatin marks such as trimethylation of histone H3 lysine 9 or 27 that regulate global gene expression patterns, are significantly altered in maturing B cells in the absence of KIF4 compared to wild type control cells. This data demonstrates that KIF4 is necessary for modulating dynamic chromatin structure via a remodeling activity that allows or restricts access to the Igh locus for CSR and antibody diversity. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 934. doi:10.1158/1538-7445.AM2011-934
18F-FDG PET/CT in the Initial Assessment and for Follow-up in Patients With Tuberculosis
Authors: Ingrid Stelzmueller, Helmut Huber, Rainer Wunn, Marina Hodolic, Michael Mandl, Bernd Lamprecht, Herwig Schinko, Franz Fellner, Andrea Skanjeti, Francesco Giammarile, Patrick M. Colletti, Domenico Rubello, Michael Gabriel
Journal: Clinical Nuclear Medicine (2015)

Purpose The aim of this retrospective study was to assess the value of 18F-FDG PET/CT in the initial evaluation and follow-up of patients with tuberculosis (TB). Patients and Methods Thirty-five patients (18 men) with pulmonary or extrapulmonary TB were included. Diagnosis of TB was based either on histology or microbiological assessment in 32 patients and was based on typical morphological features of TB in CT and improvement on antimycobacterial medication in 3 patients. Eighty-eight 18F-FDG PET/CT scans were performed at initial assessment and during treatment, on a Siemens Biograph PET/CT. Diagnostic contrast-enhanced CT scans were performed on the 40-slice multidetector CT of the PET/CT scanner. Mean (SD) anti-TB treatment duration was 16.1 (8.9) months. Results The initial 18F-FDG PET identified 64 affected regions in 34 among 35 patients, whereas CT identified 34 affected organs in 23 patients. Matching image results between PET and CT were observed at first visit in 11 patients (31.4%), with relevant differences in 23 (65.7%). In 1 patient, both modalities remained negative. During follow-up 18F-FDG PET scans, we recorded 15 cases with remission of disease, 16 with residual disease (2 patients with multidrug-resistant infection), and 4 cases with progressive disease or delayed onset of adequate immunological response. In only 3 patients, both modalities, PET and CT, showed completely equivalent results. Conclusions Both components of 18F-FDG PET/CT provide complementary information at initial evaluation and during follow-up; however, 18F-FDG showed more abnormal findings than CT. 18F-FDG PET/CT might be useful for the establishment of individualized treatment regimes, but this requires further prospective studies.
Unusual Appearance of Thromboembolism on Perfusion Lung Imaging
Authors: SHIDEH SHADAN, SUDHA CHALLA, RANDALL A. HAWKINS
Journal: Clinical Nuclear Medicine (1999)

A 46-year-old woman with advanced ovarian carcinoma had progressive dyspnea and was evaluated with ventilation and perfusion lung imaging. A characteristic pattern of multiple branching perfusion defects of a segmental nature on the perfusion scan suggested tumor microembolism and lymphangitic carcinomatosis. However, in this case, this pattern was associated with pulmonary thromboembolism and was documented by the post mortem examination. Pulmonary thromboembolism should be included among the differential diagnoses in a patient with clinical symptoms and a perfusion scan that reveals multiple branching perfusion defects.
The Diagnosis of Segmental Transplant Renal Artery Stenosis by Captopril Renography
Authors: D Mousa, D Hamilton, A Hassan, M Al-Sulaiman, F Al-Hawas, A Al-Khader
Journal: Clinical Nuclear Medicine (1999)

The captopril renogram test has been shown to be a sensitive test for the diagnosis of renal artery stenosis in native and transplanted kidneys. Most reports have involved only stenosis of the main renal artery. Although segmental renal artery stenosis has been diagnosed successfully in native kidneys, it is not clear whether the captopril renogram test can diagnose segmental renal artery stenosis in a transplanted kidney. The authors report two cases of successful identification, by the captopril renogram test, of functionally significant stenosis in an intrarenal branch of a single transplant renal artery.
I-123 MIBG Imaging and Intraoperative Localization of Metastatic Pheochromocytoma
Authors: THORA BUHL, JANN MORTENSEN, ANDREAS KJAER
Journal: Clinical Nuclear Medicine (2002)

The authors describe the diagnostic use of I-123 MIBG scintigraphy in a 61-year-old man who was thought to have a recurrence 25 years after a left adrenalectomy for a pheochromocytoma. Preoperative I-123 MIBG scintigraphy was performed twice along with intraoperative gamma probe localization of the lesions. The preoperative MIBG scintigraphy revealed three pathologic processes in the upper left abdomen, whereas computed tomographic scanning identified only one site of involvement. All three metastatic lesions were removed successfully with the aid of a gamma probe. Preoperative I-123 MIBG scintigraphy, combined with intraoperative gamma probe identification of I-123 MIBG foci, is feasible and a valuable tool to detect malignant masses possibly overlooked by other imaging techniques.
P1058 LONG-TERM EFFICACY OF TENOFOVIR IN PREVIOUSLY TREATED AND NAIVE PATIENTS. RESULTS FROM THE SPANISH CHRONIC HEPATITIS B REGISTRY (CIBERHEP)
Authors: D. Tabernero, J.M. Sánchez-Tapias, J.L. Calleja, V. Moreira, M.L. Manzano, J. Crespo, J.M. Pascasio, C.M. Fernandez, A. Aguirre, J.C. Erdozain, B. Piqueras, E. Suárez, D. Moreno, F. Gea, M. Fernandez-Bermejo, P. Sánchez-Pobre, B. de Cuenca, M. Rivero, J.J. Moreno, M. Buti
Journal: Journal of Hepatology (2014)
Endoscopic Ultrasound (EUS)-guided Fine Needle Aspiration (FNA) Accurately Diagnoses Smaller Pancreatic Neuroendocrine Tumors Compared to Computerized Tomography (CT)-guided FNA
Authors: KA Ghassemi, JR Pisegna, JJ Farrell
Journal: Endoscopy (2006)

Background: The role of EUS-guided FNA as a highly sensitive modality in the diagnosis of pancreatic adenocarcinoma is well documented. However, there is very little published data on the role of EUS-FNA in the diagnosis or management of pancreatic neuroendocrine tumors (NETs). The aim of the current study is to compare the sensitivity of EUS-FNA with that of CT-FNA in the diagnosis of pancreatic NETs.
ASSOCIATION OF AIR POLLUTION WITH INCREASED INCIDENCE OF VENTRICULAR TACHYARRHYTHMIAS RECORDED BY IMPLANTABLE CARDIOVERTER DEFIBRILLATORS
Authors: In-Soo Kim, Jungwoo Sohn, Seung-joon Lee, Jin-Kyu Park, Jae-Sun Uhm, Hui-Nam Pak, Moon-Hyoung Lee, Chang-Soo Kim, Boyoung Joung
Journal: Journal of the American College of Cardiology (2015)
Paralytic Subileus as an Adverse Effect of Amino Acid–Based Nephroprotection in a Patient Undergoing Peptide Receptor Radionuclide Therapy
Authors: Rudolf A Werner, Joachim Brumberg, Alexander Dierks, Ken Herrmann, Johannes Biko, Andreas K Buck, Constantin Lapa
Journal: Clinical Nuclear Medicine (2014)

Peptide receptor radionuclide therapy is routinely used for neuroendocrine tumors. To prevent radiopeptide retention at the proximal tubule of the kidney, positively charged amino are coinfused. However, hyperkalemia (>5.0 mmol/L) in more than three fourth of patients has been reported. In our case, the patient experienced acute hyperkalemia with blood values greater than 7.0 mmol/L with gastroparesis and subileus.
The Constitutionality of the Individual Mandate
Authors: Wendy K. Mariner, Jack M. Balkin, Ilya Somin
Journal: New England Journal of Medicine (2011)

Since the Affordable Care Act was passed, numerous lawsuits have been filed arguing that the federal mandate that individuals obtain health insurance is unconstitutional. Three appeals courts have issued mixed rulings, and the matter will probably ultimately be decided by the Supreme Court. In this video roundtable, Wendy Mariner moderates a discussion between legal scholars Jack Balkin and Ilya Somin focusing on the relevant constitutional issues.
PWE-160 Interferon Alpha Therapy for Metastatic Neuroendocrine Tumours: A Retrospective Study
Authors: E Mirvis, D Mandair, J Garcia-Hernandez, C Toumpanakis, M Mullan, M Caplin
Journal: Gut (2013)

<h3>Introduction</h3> Interferon alpha has been used in the management of NETs for over 20 years. It has generally not been popular due to perceived lack of efficacy and due to toxicity profile. Currently molecular targeted medical therapies such as mTOR inhibitors and tyrosine kinase inhibitors are promoted but studies demonstrate only modest anti-tumour effect and time to progression (TTP) with not insignificant toxicity. <h3>Aim</h3> To perform a retrospective analysis of Interferon alpha (IFNα) in patients with metastatic NET and assess efficacy and toxicity. <h3>Methods</h3> We identified 37 patients treated with IFNα 3 – 5 million units x 3 per week between 2000–2012. Mean age 58.6 (24–88) years; 26:11 male:female; 21 midgut primary, 7 pancreatic, 1 hindgut, 1 bronchial, 1 thymic and 6 unknown. Histology: G1 49%; G2 41%; G3 5%: unknown 5%. 76% were also on somatostatin analogue. 65% had recorded progressive disease at disease onset. CT/MRI imaging; urine 5HIAA and plasma chromagranin A (CgA) and toxicities were recorded. <h3>Results</h3> 9 (24%) withdrew before 3 months because of toxicity, progressive disease or death. On intention to treat analysis: 1 (3%) had complete response; 1 (3%) partial response; 26 (70%) had at least 3 months of stable disease. The median TTP was 14 months. Median 5HIAA fell from 54 to 29 umol/24h at 6 months (NS) and CgA from 138 to 121pmol/l at 6 months (NS). 38% had WHO grade 1–2 haematological toxicity and 19% grade 3–4. The only other grade 3–4 toxicity was depression in 1 patient and 22% had grade 1–2 depression. Other grade 1–2 toxicities &gt; 10% included flu-like symptoms 24%, fatigue 16%, hypothyroidism 11%, dry skin 14%. <h3>Conclusion</h3> Although there is toxicity which affects management in up to 1/3rd of patients the remaining patients tolerated therapy well. IFNα demonstrated efficacy in at least inducing or maintaining stable disease in most patients (76%). The median TTP is at least similar to other molecular targeted therapies. Those patients who were going to be intolerant or progress usually did so within the first 3 months of treatment. It would be appropriate to perform prospective randomised studies utilising IFNα and also better assess quality of life. <h3>Disclosure of Interest</h3> None Declared.
THE ANTI-PLATELET EFFECT OF DIFFERENT LOADING DOSE OF TICAGRELOR IN PATIENTS WITH NON-ST ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY
Authors: Liu Huiliang, Yu-Jie Wei, Zhi-Geng Jin, Peng Ding, Sheng-Li Yang, Jian-Ping Luo, Dong-Xing Ma, Ying Liu, Wei Han, Jiao Zhang, Tianchang Li, Bing Wang, Ming-Sheng Wang, Yun-Tian Li, Jian-Jun Zhang, Yi-Hong Ren, Qiang Tang
Journal: Journal of the American College of Cardiology (2016)
SAT0206 Role of Tissue Doppler Echocardiography in Detecting Preclinical Cardiac Involvement in Systemic Sclerosis Patients
Authors: M. Limonta, E. Lupi, M. Gori, P. Scuri, P. Baio, V. Duino, A. Gavazzi, M. Senni
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Primary myocardial involvement is common in systemic sclerosis (SSc), but often underestimated. Clinically apparent myocardial involvement has significant therapeutic implications and is considered an important prognostic factor. Cardiac involvement may occur years before clinical manifestation. Limited data are available on preclinical cardiac involvement assessment. In this study we investigated whether preclinical cardiac dysfunction can be detected by echocardiographic Tissue Doppler Imaging (TDI) in SSc patients. <h3>Methods</h3> We prospectively studied 33 consecutive female patients (mean age ±SD 48.6±8.5 years)with SSc, without pulmonary hypertension, arterial hypertension or renal failure, and in I NYHA class. Results were compared with 16 age and sex-matched healthy controls (mean age ±SD 48.8 ±5.6 years; p=0.93). patients underwent standard echocardiography, along with measurements of longitudinal velocities by TDI to assess right ventricular and left ventricular (LV) contractility and LV diastolic function. <h3>Results</h3> Systolic right ventricular function, as measured by peak systolic tricuspid annular velocity, was lower in patients than in controls (mean±SD 13.3±2% vs 14.8±1.4%; p&lt;0.01). PASP was higher in the patient group (mean±SD 26.8±5.5% vs 20.8±2.9%; p&lt;0.0001), even if within the normal range. Patients with SSc had a worse LV relaxation compared with the controls. Medial mitral annulus early diastolic velocity was lower in patients than in controls (patients: mean±SD 8.3±2.2%; controls 11.2±1.7%; p&lt;0.00003), while E/E' was significantly higher (patients: mean±SD 10±2.3%; controls 7.4±1.5%; p&lt;0.0002). Both groups had similar LV ejection fraction (patients: mean±SD 61.9±5.2%; controls 62.5±3.9%; p&lt;0.67), while peak systolic mitral annular velocity as measured by TDI (medium value between septal, lateral, inferior and anterior ones) was significantly lower in patients than in controls (mean±SD 8.2±2% vs 10.1±1.1%; p&lt;0.0005). <h3>Conclusions</h3> Evaluation of ventricular function by TDI is an effective tool to detect preclinical systolic and diastolic cardiac involvement in SSc patients, when therapeutics are supposed to be more affective. <h3>Disclosure of Interest</h3> None Declared
Genetics of Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA) Syndrome
Authors: Lori Broderick, Daniela Carvalho, Anthony Magit, Wen Jiang, Shelby Leuin, Marcella Bothwell, Donald Kearns, Seth Pransky, Hal M. Hoffman
Journal: Journal of Allergy and Clinical Immunology (2013)
Acid-Base Effects of Topical Mafenide Acetate in the Burned Patient
Authors: Martin G. White, Morris J. Asch
Journal: New England Journal of Medicine (1971)

Abstract Ten burned patients were observed for 24 hours after treatment with topical mafenide acetate cream. This drug was rapidly absorbed systemically and converted to p-carboxybenzenesulfonamide. Both agents are carbonic anhydrase inhibitors. The highest blood levels of mafenide and p-carboxybenzenesulfonamide occurred during the second to the fourth hour in patients with decreased renal function and extensive areas of partial-thickness burn. The urine became persistently alkaline in nine of the 10 patients, suggesting renal carbonic anhydrase inhibition. Six of the patients with the highest drug blood levels had a transient increase in the arterialalveolar carbon dioxide tension gradient during the first to the 12th hours of mafenide therapy, suggesting inhibition of red-cell carbonic anhydrase. At 24 hours, both drug levels and the difference between arterial and alveolar carbon dioxide tension had returned to pretreatment values. Despite renal and red-cell carbonic anhydrase inhibition, no consisten...
A phase I study of therapeutic amplitude-modulated electromagnetic fields (THERABIONIC) in advanced tumors
Authors: B. Pasche, A. Barbault, B. Bottger, F. Bomholt, N. Kuster
Journal: Journal of Clinical Oncology (2007)

14072 Background: In vitro studies suggest that low levels of amplitude-modulated electromagnetic fields may modify cell growth. We have identified specific frequencies that may block cancer cell growth. We have developed the THERABIONIC device, a portable and programmable emitter of a 27.12 MHz radiofrequency signal, amplitude-modulated at cancer-specific frequencies ranging from 0.2 to 23,000 Hz with high precision. The device is connected to a spoon-like coupler, which is placed in the patient’s mouth during treatment. The levels of absorbed electromagnetic energy are well below safety limits. Methods: A phase I study consisting of three daily 40 min treatments until disease progression or death. From March 2004 to September 2006, 24 patients with advanced solid tumors were enrolled. The median age was 57.0 ± 12.2 years. 16 patients were female. As of January 2007, 5 patients are still on therapy, 13 patients died of tumor progression, 2 patients are lost to follow-up and one patient withdrew consent. The most common tumor types were breast (7), ovary (5) and pancreas (3). 21 patients had received prior systemic therapy and 16 had documented tumor progression prior to study entry. Results: The median duration of therapy was 15.7 ± 19.9 weeks (range: 0.4–72.0 weeks). There were no NCI grade 2/3/4 toxicities. Three patients experienced grade 1 fatigue during and immediately after treatment. 12 patients reported severe pain prior to study entry. Two of them reported significant pain relief with THERABIONIC treatment. Objective response could be assessed in 13 patients, 6 of whom also had elevated tumor markers. 6 additional patients could only be assessed by tumor markers. Among patients with progressive disease at study entry, one had a partial response for &gt; 14.4 weeks associated with &gt; 50% decrease in CEA, CA 125 and CA 15–3 (previously untreated metastatic breast cancer); one patient had a 50% decrease in CA 19–9 for 12.4 weeks (recurrent and previously systemically-treated pancreatic cancer). Among patients with stable disease at enrollment, four patients maintained stable disease for 17.0, &gt; 19.4, 30.4 and &gt; 63.4 weeks. Conclusions: THERABIONIC is a safe and promising novel treatment modality for advanced cancer. No significant financial relationships to disclose.
Abstract 329: Identification of the breakpoints of two chromosome translocations involving chromosomes 4 and 7 observed in two murine mammary carcinomas
Authors: María B. Pampena, Susana Merani, Claudia Lanari, Victoria T. Fabris
Journal: Cancer Research (2010)

Abstract The translocation between chromosomes 4 and 7, T(4;7), was observed in two different mammary carcinomas from the medroxyprogesterone acetate (MPA) mouse breast cancer model which have acquired a hormone independent (HI) phenotype (C7-2-HI and C4-HI). We had developed a cell line from the C7-2-HI tumor, the MC7-L2A cells, which retain the chromosome translocation T(4;7), and provide an easy tool to obtain metaphases. G-banding analysis showed that the breakpoint on chromosome 4 is located on the band 4E in the C7-2-HI tumor, whereas in the C4-HI tumor, it is located on the region 4C4-4D3. However, the breakpoint on chromosome 7 is located near the centromere in both tumors. Further experiments using fluorescence in situ hybridization (FISH) in MC7-L2A cells have shown that the breakpoint of the translocation involved the chromosome bands 4E2 and 7A1-A2. The aim of this project is to elucidate whether these breakpoints are involving new gene rearrangements that might participate in the acquisition of hormone independency. In this study we focused in determining if the break in chromosome 7 is located on the same band in both HI tumors. A detailed analysis in MC7-L2A cells using FISH with different DNA probes, spanning the region 7A1-7A2, showed that the breakpoint is located on chromosome 7A1 and not on band 7A2. However, a different picture was observed in metaphases obtained from C4-HI tumor cells, in which the probes corresponding to region 7A1-7B1 hybridized only to normal chromosome 7, but not to the translocation T(4;7). These results indicate that the breakpoints on chromosomes 4 and 7, although involving the same chromosomes, are located on different regions in the T(4;7) translocations, suggesting that they may be random breakpoints. Even though we could not associate this breakpoint with the hormone-independent phenotype, the identification of the sites of chromosome breaks may be relevant to understand the biology of each HI tumor. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 329.
TCTAP C-020 Acute Myocardial Infarction with Left Main Coronary Artery Total Occlusion Stabilized by Primary Balloon Angioplasty and Subsequently Underwent Successful Coronary Artery Bypass Graft Surgery
Authors: Hou Tee Lu, Kai Ping Ang, Simon Vendargon, Abdul Rahman Ismail
Journal: Journal of the American College of Cardiology (2015)
Abstract C33: N-terminal fragment of Bit1 apoptotic protein induces autophagy in tumor cells
Authors: Renwei Chen, Gary B. Braun, Xiuquan Luo, Kazuki N. Sugahara, Tambet Teesalu, Erkki Ruoslahti
Journal: Cancer Research (2011)

Abstract Bit1 is a proapoptotic mitochondrial protein associated with anoikis, cell death resulting from the loss of cell attachment to extracellular matrix. Upon cell detachment, Bit1 is released into the cytoplasm, where it complexes with the Groucho family protein amino-terminal enhancer of split, and triggers cell death through a caspase-independent pathway. Bit1 consists of 179 amino acids; the N-terminal 62 amino acid mitochondrial localization domain, a transmembrane domain, and the C-terminal peptidyl-tRNA hydrolase domain. In the present study, we localized the Bit1 cell death domain (BCDD) to the N-terminal 62 amino acids of Bit1 by introducing truncated Bit1 proteins into the cytoplasm with cDNAtransfection and protein transduction. BCDD was more potent than the full-length Bit1 protein, when equivalent amounts of cDNA was transfected. Treatment of cultured prostate and breast cancer cells with recombinant proteins in which BCDD was fused with two cell-internalizing peptides, one of which is tumor specific, also caused cell death. Bit1 and BCDD shared the characteristics previously attributed to Bit1-induced cell death. In addition, we found that the cells exhibited the signs of autophagy. These results define the cell death domain in Bit1 and reveal autophagy as the main mechanism of Bit1-induced cell death. Tumor-targeted exogenous BCDD may have potential as an anticancer agent. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the Second AACR International Conference on Frontiers in Basic Cancer Research; 2011 Sep 14-18; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2011;71(18 Suppl):Abstract nr C33.